About the Company
precision biosciences, inc. is a biotechnology company located in durham, north carolina, united states.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
218
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DTIL News
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform ...
Buy Rating Affirmed for Precision BioSciences on Promising Gene Editing Prospects and Strong Financials
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL – Research Report). The ...
Precision Biosciences files patent for engineered meganuclease for treating hepatitis B virus infections
Discover Precision Biosciences' groundbreaking patent for engineered meganucleases targeting Hepatitis B virus, offering improved characteristics for treating infections and hepatocellular carcinoma.
Buy Rating Affirmed for Precision BioSciences as Milestones in Gene Editing Technology Loom
Analyst Soumit Roy of JonesTrading maintained a Buy rating on Precision BioSciences (DTIL – Research Report), retaining the price target ...
Precision BioSciences: Q4 Earnings Snapshot
DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Precision BioSciences Inc. (DTIL) on Wednesday reported a loss of $16.3 million in its fourth quarter. The Durham, North Carolina-based company said it had a ...
Precision Biosciences Flat On New Product Development
AstraZenca Buys Fusion for $2 <li /> Kroger Set to Sell Pharmacy Arm <li /> Howard Hughes Links up with Discovery Land <li /> ...
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene e ...
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene ...
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on ...
Precision BioSciences Q4 Earnings Preview
The consensus EPS Estimate is -$2.03 (-680.8% Y/Y) and the consensus Revenue Estimate is $14.46M (+36.5% Y/Y).Over the last 1 year, DTIL has beaten EPS estimates 50% of the time and has beaten revenue ...
Earnings Preview: Precision BioSciences
Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-2.05. Precision BioSciences bulls will hope to hear the company announce they've not only beaten that estimate ...
Loading the latest forecasts...